
Condition Guide
Metabolic enhancement and body composition
GLP-1 agonists like Semaglutide and Tirzepatide have revolutionized the fat loss peptide space. Originally developed for diabetes management, these compounds have shown remarkable weight loss effects. Community reports consistently highlight significant appetite reduction and steady weight loss, though experiences vary widely based on dosing, diet, and lifestyle factors.
Tirzepatide and Semaglutide are the most discussed weight loss peptides, with Tirzepatide showing slightly higher average weight loss in community reports (15-20% body weight vs 10-15% for Semaglutide). Both work primarily through appetite suppression. Tesamorelin is popular specifically for reducing visceral fat.
Ranked by how frequently users report positive results

A small molecule NNMT inhibitor that preserves NAD+ levels and activates SIRT1 (the 'longevity gene'). Primarily taken orally - trending in longevity clinic protocols.

A GLP-1 receptor agonist widely reported for significant weight loss and appetite suppression.

A dual GIP/GLP-1 receptor agonist reported for even more significant weight loss than Semaglutide.

A triple agonist (GIP/GLP-1/Glucagon) in clinical trials showing exceptional weight loss results.

A GHRH analog FDA-approved for HIV lipodystrophy, used off-label for body composition and anti-aging.

A modified GH fragment reported for fat loss without the growth-promoting effects of full GH.
6
Peptides in this category
9
Total benefits documented
5-Amino-1MQ
Most popular choice
Take our guided quiz to find the right peptides for your goals.
Find Your Stack
A small molecule NNMT inhibitor that preserves NAD+ levels and activates SIRT1 (the 'longevity gene'). Primarily taken orally - trending in longevity clinic protocols.

A GLP-1 receptor agonist widely reported for significant weight loss and appetite suppression.

A dual GIP/GLP-1 receptor agonist reported for even more significant weight loss than Semaglutide.
Common questions about peptides for fat loss
Community reports vary widely, but most users report 10-15% of body weight over 6-12 months. Some report 20%+ with strict diet adherence. Weight loss typically starts slow (1-2 lbs/week) and accelerates as doses increase.
The most common reported side effects are nausea (especially during dose increases), constipation, and reduced appetite. Most users report side effects diminish after 2-4 weeks. Starting with low doses and titrating slowly helps minimize discomfort.
Tirzepatide (dual GIP/GLP-1 agonist) shows higher average weight loss in both clinical trials and community reports. However, it's newer and more expensive. Many users start with Semaglutide due to lower cost and switch if needed.
This is a common concern. Many users report some weight regain after stopping, typically 30-50% of lost weight over 6-12 months. Users who maintain diet and exercise habits during treatment report better long-term maintenance.